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406 Domiciliary assistance in cystic ﬁbrosis: the experience of a
regional center
F. Patriarchi1, T. Tonelli1, F. Annese1, B. Giacomodonato1, D. Russo1, A. Monni1,
A.M. Ferrazza1, F. Alatri1, S. Quattrucci1. 1University of Rome ‘Sapienza’,
Department of Pediatrics, Rome, Italy
The domiciliary assistance (DA) is an important tool that reduces the number of
hospitalization and the length of hospital stay improving the quality of life. The
reduction in sanitary costs and in multi-drug-resistance microorganisms infections
can also be obtained.
Methods: In order to evaluate the feasibility of DA in patients with cystic ﬁbrosis
(CF), we performed a project that provides assistence to: 1. family with newborn
diagnosis of CF (January 2006-November 2009), normally requiring about 7.5 days
of hospital stay, and 2. CF patients with bronchopulmonary exacerbation (BPE)
needing iv antibiotic administration (from March to December 2009).
Results: During our experience, 29 families with newborn diagnosis of CF received
three mounts cycles of DA including monthly doctor and a social assistant visit and
twice a week physiotherapist visits. Furthermore, 15 CF adult patients (10−52 yr)
with BPE underwent 17 DA cycles including home iv antibiotics administration
(15±5 days), 3 doctor visits, 4 nurse and physiotherapist visits and 2 social assistant
visits; only 3 patients started the antibiotic administration during a short hospital
admission (8 days). No adverse events, complications or needs of hospital admission
occurred during the period of DA. The project permitted to avoid 217 days of
hospitalization for newborns and 248 for patients with BPE.
Conclusion: A multidisciplinary DA provides a comprehensive help to CF patients
and can safety manage different needs (e.g. physiotherapy, antibiotics administra-
tion, social support) in different settings (e.g. new diagnosis, BPE) reducing the
hospital stay and improving the quality of life.
407 Totally implantable vascular access devices − review of
complications at a UK centre
D. Nazareth1, H. Tan1, C. Cowperthwaite1, M. Ledson1, M. Walshaw1,
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Totally implantable venous access devices (TIVADs) have revolutionised treatment
for patients with poor peripheral venous access or who require repeated courses of
IV therapy, but studies show a 42−54% complication rate. To look at this further,
we reviewed all 24 TIVAD complications (10 venous thrombosis, 6 infection, 3 port
occlusion, 3 line split, 1 pneumothorax and 1 cellulitis) in 16 patients (9 female)
over an 18 month period at our large centre (250 adult CF patients), where 73
(29%) currently use a TIVAD. The average age of the device when intervention
was needed was 42 months (range >1−120).
As regards infection, positive blood or port tip cultures were not related to sputum
microbiology and 5 (80%) infections developed within 2 months of the last
IV therapy.
As regards thrombosis, 9 (90%) developed within 1 year of insertion, 3 cases
recurring despite formal anti-coagulation and radiological imaging to determine
the most suitable insertion site. The site of thrombus was not always at the site of
the device, with a higher incidence of thrombus formation in femoral devices (5,
40%).
As regards occlusion, although urokinase was always deployed, all had to be
removed eventually.
As regards mechanical problems, split lines (including 1 complete fracture) all
occurred during antibiotic therapy.
In conclusion, we have found complications in 22% of our TIVADS over an
18 month period: no common precipitating factor was noted, but the femoral route
was more troublesome. The study reiterates the need to take care of these useful
devices, especially the need for sterile precautions during times of access and regular
anticoagulant ﬂushes during times of disuse.
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Standards for intravenous antibiotic therapy (IVAT) in hospitals are robust, yet there
is no consensus on best practice when IVAT is administered by lay caregivers at
home. We are conducting a multi-centre study to assess the impact and safety of
Home-IVAT for children with cystic ﬁbrosis. This required the development of a
tool to survey the range of risk.
Methods: The risk tool was constructed with professionals and caregivers then
piloted for its content, face validity, and acceptability using focus groups at different
sites. It is hypothesised to predict outcomes for Home-IVAT: (i) caregiver mood,
(ii) adverse drug events, and (iii) adherence.
Findings: Data from 45 cases (25 males, 20 females) aged 2−14 years with FEV1%
predicted of 28–113% [Mean(SD), 73.3(18.7)] at 16 sites are reported. The majority
(87%) of caregivers delivered 2 antibiotics; in 82% one was an aminoglycoside; 31%
conducted this procedure every 3 months; and, 38% of children had a peripheral
cannula or long line. Aminoglycosides were mostly given once per day (60%), came
ready prepared (69%) and delivered with an infusion device (61%). Other antibiotics
were administered by bolus or syringe driver (76%), and given three times per day
(77%). Some lay caregivers (9−11%) reconstituted these medications and 50% of
the centres chose not to equip families with an anaphylaxis kit. After controlling for
FEV1% predicted, not having an implantable venous access device was associated
with caregiver depression [regression coefﬁcient (B) = 4.18 (0.7, 7.66), p = 0.025].
Conclusions: These ﬁndings will help CF teams to identify factors that impact
negatively on families undertaking this complex health care task at home.
409 Nursing practice with intravenous antibiotic home treatment for
patients with cystic ﬁbrosis − a Scandinavian Nurses Specialist
Group − CF study
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Background: In Scandinavia there are seven CF-centres: Two in Denmark, four
in Sweden and one in Norway. Sweden and Norway have shared care between
CF-centres and local hospitals. Denmark has centralised CF-centre care. During
the last twenty years there has been an accepted practice for iv antibiotic home
treatment for patients with CF in Denmark, Norway and Sweden.
Aim: To make a survey of nursing practice with iv antibiotic home treatment for
patients with CF with focus on planning, information and education, cooperation
and responsibility.
Method: The questionnaire was translated to each national language, and sent
to nurses working with CF at cooperating local/regional hospitals in Scandinavia.
Numbers of questionnaires: Denmark 17 out − 16 in, Sweden 71 out − 56 in,
Norway 39 out − 18 in.
Results: The study indicates several similarities in nursing practice, but also some
differences. Similarities: All patients are instructed − mostly by nurses, ﬁrst dose
at hospital, serum concentation, individual asessment of ﬁtness for home treatment.
Few had written instructions or reeducation. Differencies: Anafylactic readiness,
person responsible for mixing the antibiotic, treatment duration, adult attendence
during infusion, examination at treatment ending, esessment of need for sick leave.
Conclusion: A quality standard for best practice and education for home treatment
with intravenous antibiotic for patients with CF is needed. Regular evaluation of
practice to secure the best practice. Shared care is also a challenge concerning home
teatment with intravenous antibiotic.
